BR112020021269A2 - Construções de anticorpo anti-ror - Google Patents

Construções de anticorpo anti-ror Download PDF

Info

Publication number
BR112020021269A2
BR112020021269A2 BR112020021269-5A BR112020021269A BR112020021269A2 BR 112020021269 A2 BR112020021269 A2 BR 112020021269A2 BR 112020021269 A BR112020021269 A BR 112020021269A BR 112020021269 A2 BR112020021269 A2 BR 112020021269A2
Authority
BR
Brazil
Prior art keywords
domain
antigen
amino acid
ror
binding molecule
Prior art date
Application number
BR112020021269-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Lucas Bailey
Qufei Li
Malgorzata Agnieszka Nocula-Lugowska
Bryan Glaser
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Publication of BR112020021269A2 publication Critical patent/BR112020021269A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112020021269-5A 2018-04-18 2019-04-18 Construções de anticorpo anti-ror BR112020021269A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659635P 2018-04-18 2018-04-18
US62/659,635 2018-04-18
PCT/US2019/028051 WO2019204564A1 (en) 2018-04-18 2019-04-18 Anti-ror antibody constructs

Publications (1)

Publication Number Publication Date
BR112020021269A2 true BR112020021269A2 (pt) 2021-03-16

Family

ID=68239890

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020021269-5A BR112020021269A2 (pt) 2018-04-18 2019-04-18 Construções de anticorpo anti-ror

Country Status (15)

Country Link
US (2) US12084496B2 (cg-RX-API-DMAC7.html)
EP (1) EP3797122A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021522162A (cg-RX-API-DMAC7.html)
KR (1) KR102999339B1 (cg-RX-API-DMAC7.html)
CN (1) CN112384533A (cg-RX-API-DMAC7.html)
AU (2) AU2019256431B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020021269A2 (cg-RX-API-DMAC7.html)
CA (1) CA3097704A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092202A1 (cg-RX-API-DMAC7.html)
IL (2) IL316574A (cg-RX-API-DMAC7.html)
MX (4) MX2020010881A (cg-RX-API-DMAC7.html)
MY (1) MY207121A (cg-RX-API-DMAC7.html)
PH (1) PH12020551716A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202010235QA (cg-RX-API-DMAC7.html)
WO (1) WO2019204564A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3529269T3 (da) * 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
IL300760A (en) * 2020-08-24 2023-04-01 Epimab Biotherapeutics Hk Ltd Anti-ROR1 antibodies and related bispecific binding proteins
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ror1結合タンパク質を発現する細胞を培養する方法
US20230296605A1 (en) * 2022-03-18 2023-09-21 Novascope Biochips Inc. Antibody for porcine reproductive and respiratory syndrome virus and uses thereof
IL317782A (en) * 2022-06-30 2025-02-01 Sutro Biopharma Inc Anti-ROR1 antibodies and conjugates thereof, compositions containing anti-ROR1 antibodies or conjugates thereof, and methods for preparing and using anti-ROR1 antibodies and conjugates thereof
WO2024207177A1 (en) * 2023-04-04 2024-10-10 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
IL318546A (en) * 2022-07-26 2025-03-01 Aimed Bio Inc Anti-ROR1 antibody and its uses
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
GB202216284D0 (en) * 2022-11-02 2022-12-14 Ucl Business Ltd Self-regulation
CN120813602A (zh) * 2022-12-20 2025-10-17 英克特诺治疗公司 用于治疗癌症的组合疗法
KR20260056331A (ko) * 2023-07-20 2026-04-24 엑셀리시스, 인코포레이티드 활성화 가능한 티로신-단백질 키나제 막 수용체(ror) 항체-약물 접합체 및 이의 용도
JP2026525959A (ja) * 2023-07-20 2026-08-04 エグゼリクシス, インコーポレイテッド チロシン-タンパク質キナーゼ膜受容体1(ror1)抗体-薬物コンジュゲート、及びその使用
KR20260044208A (ko) * 2023-07-20 2026-04-01 엑셀리시스, 인코포레이티드 활성화 가능한 ror 결합제 및 이의 용도
AU2024406068A1 (en) * 2023-12-20 2026-07-30 Antalgenics, S.L. Phospholipase c inhibitor peptides and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US9316646B2 (en) * 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
US9242014B2 (en) * 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
EP2646469B1 (en) * 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
PL3489261T3 (pl) * 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
JP2017536341A (ja) 2014-10-09 2017-12-07 エンクマフ アーゲー 卵巣がんの処置における使用のためのCD3εおよびROR1に対する二特異性抗体
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016142768A1 (en) * 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
HK1253507A1 (zh) * 2015-05-18 2019-06-21 Eureka Therapeutics, Inc. 抗 ror1 抗体
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
CN109311982A (zh) 2016-01-20 2019-02-05 斯克利普斯研究所 Ror2抗体组合物和相关方法
CA3011419A1 (en) * 2016-01-22 2017-07-27 Janssen Biotech, Inc. Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
DK3529269T3 (da) 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same

Also Published As

Publication number Publication date
MY207121A (en) 2025-01-31
WO2019204564A9 (en) 2019-12-12
MX2025001900A (es) 2025-04-02
EP3797122A4 (en) 2022-04-20
EP3797122A1 (en) 2021-03-31
JP2023168551A (ja) 2023-11-24
US12084496B2 (en) 2024-09-10
MX2025001902A (es) 2025-04-02
JP2021522162A (ja) 2021-08-30
US20240392002A1 (en) 2024-11-28
JP2025137618A (ja) 2025-09-19
AU2019256431B2 (en) 2026-01-15
WO2019204564A1 (en) 2019-10-24
SG11202010235QA (en) 2020-11-27
KR20200143470A (ko) 2020-12-23
CA3097704A1 (en) 2019-10-24
AU2019256431A1 (en) 2020-11-05
CN112384533A (zh) 2021-02-19
MX2025001906A (es) 2025-04-02
IL278061A (en) 2020-11-30
IL316574A (en) 2024-12-01
US20210155692A1 (en) 2021-05-27
PH12020551716A1 (en) 2021-07-26
MX2020010881A (es) 2020-11-09
AU2026202585A1 (en) 2026-04-30
EA202092202A1 (ru) 2021-07-23
KR102999339B1 (ko) 2026-07-31

Similar Documents

Publication Publication Date Title
US20240392002A1 (en) Anti-ror antibody constructs
JP7591015B2 (ja) 抗体構築物
BR112020021279A2 (pt) Constructos de anticorpos trispecíficos trivalentes
JP6366195B2 (ja) 炎症性疾患の予防又は治療剤
TW202246322A (zh) 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
US20220213225A1 (en) Multispecific treg binding molecules
AU2013253581A1 (en) Anti-human CD69 antibody, and use thereof for medical purposes
CA3213285A1 (en) Bioengineered immunomodulatory fusion protein compositions
TW202128752A (zh) 抗il﹘27抗體及其用途
CN117412767A (zh) C-x-c基序趋化因子受体6(cxcr6)结合分子及其使用方法
CN113166248A (zh) 人源化抗人ox40单克隆抗体及其制备方法和用途
WO2021213245A1 (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US20220153844A1 (en) Multispecific treg binding molecules
TW202336035A (zh) 治療自體免疫疾病及癌症之方法及組成物
EA048615B1 (ru) Конструкции антител к ror
TW202608923A (zh) Ltbr結合分子及其用途
TW202615477A (zh) 雙特異性抗體及其用途
HK40064218B (en) Anti-gal3 antibodies and uses thereof

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122026008131-3 PROTOCOLO 870260031312 EM 02/04/2026 17:29.O PEDIDO FOI DIVIDIDO NO BR122026008131-3 PROTOCOLO 870260031312 EM 02/04/2026 17:29.